polyjet sl100688 Search Results


polyjet sl100688  (Biocompare)
90
Biocompare polyjet sl100688
Engineering and characterization of targeted core-shell NPs carrying pHR-pCas9. (A) Illustration for the fabrication of targeted core-shell NPs carrying pHR-pCas9. pHR, a plasmid for homologous recombination; pCas9, a plasmid for CRISPR associated protein 9. (B) Effects of N/P ratios on the sizes and polydispersity (PDI) indexes of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The sizes and PDI indexes were measured by dynamic light scattering (DLS). N/P ratio, nitrogen/phosphorus ratio. Data are presented as mean ± standard deviation (n = 3). (C) Effects of N/P ratios on the zeta potential values of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The zeta potential values were measured by DLS. Data are presented as mean ± standard deviation (n = 3). (D) Encapsulation capabilities of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). The encapsulation capabilities were determined by electrophoretic mobility shift assay (EMSA). Free pHR-pCas9 were used as the control. (E) Transfection efficiencies of human breast cancer MDA-MB-231 cells. The cells were treated with core NPs carrying pHR-pCas9, and with targeted core-shell NPs carrying pHR-pCas9, respectively. <t>Polyjet</t> carrying pHR-pCas9 was used as the positive control. Data are presented as mean ± standard deviation (n = 3). (F) Transmission electron microscope images of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). Scale bar, 200 nm.
Polyjet Sl100688, supplied by Biocompare, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyjet sl100688/product/Biocompare
Average 90 stars, based on 1 article reviews
polyjet sl100688 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Engineering and characterization of targeted core-shell NPs carrying pHR-pCas9. (A) Illustration for the fabrication of targeted core-shell NPs carrying pHR-pCas9. pHR, a plasmid for homologous recombination; pCas9, a plasmid for CRISPR associated protein 9. (B) Effects of N/P ratios on the sizes and polydispersity (PDI) indexes of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The sizes and PDI indexes were measured by dynamic light scattering (DLS). N/P ratio, nitrogen/phosphorus ratio. Data are presented as mean ± standard deviation (n = 3). (C) Effects of N/P ratios on the zeta potential values of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The zeta potential values were measured by DLS. Data are presented as mean ± standard deviation (n = 3). (D) Encapsulation capabilities of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). The encapsulation capabilities were determined by electrophoretic mobility shift assay (EMSA). Free pHR-pCas9 were used as the control. (E) Transfection efficiencies of human breast cancer MDA-MB-231 cells. The cells were treated with core NPs carrying pHR-pCas9, and with targeted core-shell NPs carrying pHR-pCas9, respectively. Polyjet carrying pHR-pCas9 was used as the positive control. Data are presented as mean ± standard deviation (n = 3). (F) Transmission electron microscope images of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). Scale bar, 200 nm.

Journal: Bioactive Materials

Article Title: Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer

doi: 10.1016/j.bioactmat.2021.10.007

Figure Lengend Snippet: Engineering and characterization of targeted core-shell NPs carrying pHR-pCas9. (A) Illustration for the fabrication of targeted core-shell NPs carrying pHR-pCas9. pHR, a plasmid for homologous recombination; pCas9, a plasmid for CRISPR associated protein 9. (B) Effects of N/P ratios on the sizes and polydispersity (PDI) indexes of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The sizes and PDI indexes were measured by dynamic light scattering (DLS). N/P ratio, nitrogen/phosphorus ratio. Data are presented as mean ± standard deviation (n = 3). (C) Effects of N/P ratios on the zeta potential values of core NPs carrying pHR-pCas9, and targeted core-shell NPs carrying pHR-pCas9. The zeta potential values were measured by DLS. Data are presented as mean ± standard deviation (n = 3). (D) Encapsulation capabilities of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). The encapsulation capabilities were determined by electrophoretic mobility shift assay (EMSA). Free pHR-pCas9 were used as the control. (E) Transfection efficiencies of human breast cancer MDA-MB-231 cells. The cells were treated with core NPs carrying pHR-pCas9, and with targeted core-shell NPs carrying pHR-pCas9, respectively. Polyjet carrying pHR-pCas9 was used as the positive control. Data are presented as mean ± standard deviation (n = 3). (F) Transmission electron microscope images of core NPs carrying pHR-pCas9 (left), and targeted core-shell NPs carrying pHR-pCas9 (right). Scale bar, 200 nm.

Article Snippet: Polyjet (# SL100688) was purchased from Biocompare (Beijing local agent, China).

Techniques: Plasmid Preparation, Homologous Recombination, CRISPR, Standard Deviation, Zeta Potential Analyzer, Encapsulation, Electrophoretic Mobility Shift Assay, Control, Transfection, Positive Control, Transmission Assay, Microscopy